Cardiology Department, Hospital IMED Elche, Elche, Spain; Grupo de Investigación Cardiovascular, Universidad Miguel Hernández, Elche, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
Ginaecology Laboratory, Hospital Universitario de San Juan, Alicante, Spain.
Clin Biochem. 2024 Oct;131-132:110814. doi: 10.1016/j.clinbiochem.2024.110814. Epub 2024 Aug 31.
Several biomarkers are characteristically elevated in patients with acute heart failure (AHF). Our hypothesis was they could predict early changes in left ventricular (LV) characteristics in acute coronary syndrome (ACS) patients. The objective of this study was two-fold: a) compare circulating concentrations of NT-pro BNP, CA-125, ST2, galectin-3 and pro-adrenomedullin among 4 groups of individuals (healthy controls; patients with ACS without AHF; patients with ACS and AHF and patients admitted for AHF); and b) evaluate whether these biomarkers predict adverse LV remodeling and ejection fraction changes in ACS.
6 biomarkers (NT-pro BNP, CA-125, ST2, galectin-3, pro-adrenomedullin and C-reactive) were measured within the first 48 h of admission. Echocardiograms were performed during admission and at 3 months. Variables associated with LV end-diastolic volume (EDV) and ejection fraction (LVEF) change were assessed by multivariate linear regression.
We analyzed 51 patients with ACS, 16 with AHF and, 20 healthy controls. NT-pro BNP and ST2 concentrations were elevated at similar values in patients admitted for AHF and ACS complicated with HF but CA-125 concentrations were higher in AHF patients. NT-pro BNP concentrations were positively correlated with CA-125 (rho = 0.58; p < 0.001), ST2 (rho = 0.58; p < 0.001) and galectin-3 (rho = 0.37; p < 0.001) Median change (median days was 83 days after) in EDV and LVEF was 5 %. CA-125 concentrations were positively associated to LV EDV change (β-coefficient 1.56) and negatively with LVEF trend (β-coefficient = -0.86). No other biomarker predicted changes in EDV or LVEF.
CA-125 correlates with early LV remodeling and LVEF deterioration in ACS patients.
几种生物标志物在急性心力衰竭（AHF）患者中明显升高。我们的假设是，它们可以预测急性冠状动脉综合征（ACS）患者左心室（LV）特征的早期变化。本研究的目的有两个：a）比较 4 组个体（健康对照者；无 AHF 的 ACS 患者；有 AHF 的 ACS 患者和因 AHF 入院的患者）循环中 NT-pro BNP、CA-125、ST2、半乳糖凝集素-3 和前肾上腺髓质素的浓度；b）评估这些生物标志物是否可预测 ACS 患者不良的 LV 重构和射血分数变化。
在入院的前 48 小时内测量了 6 种生物标志物（NT-pro BNP、CA-125、ST2、半乳糖凝集素-3、前肾上腺髓质素和 C 反应蛋白）。在入院期间和 3 个月时进行超声心动图检查。通过多元线性回归评估与 LV 舒张末期容积（EDV）和射血分数（LVEF）变化相关的变量。
我们分析了 51 例 ACS 患者、16 例 AHF 患者和 20 例健康对照者。因 AHF 和 ACS 合并 HF 入院的患者的 NT-pro BNP 和 ST2 浓度升高，但 CA-125 浓度更高。NT-pro BNP 浓度与 CA-125（rho=0.58;p<0.001）、ST2（rho=0.58;p<0.001）和半乳糖凝集素-3（rho=0.37;p<0.001）呈正相关。EDV 和 LVEF 的中位数变化（中位数天数为 83 天后）为 5%。CA-125 浓度与 LV EDV 变化呈正相关（β 系数 1.56），与 LVEF 趋势呈负相关（β 系数=-0.86）。其他生物标志物均未预测 EDV 或 LVEF 的变化。
CA-125 与 ACS 患者的早期 LV 重构和 LVEF 恶化相关。
